Sutro Biopharma, Inc.
310 Utah Avenue
Suite 150
South San Francisco
California
94080
United States
Tel: 650-392-8412
Fax: 650-872-8924
Website: http://www.sutrobio.com/
Email: busdev@sutrobio.com
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. develops best-in-class antibody-drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Sutro’s discovery and development efforts are driven by the Xpress CF™ platform, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro’s make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks, enabling broader and deeper biologics discovery and development efforts than can be accomplished with current cell-based expression technologies. Sutro’s technology platform allows production of proteins by bypassing the cell completely, cutting the pre-clinical development period by several months and can be done on any scale in just 8-10 hours.
Once identified, production of protein drug candidates can be rapidly and predictably scaled in Sutro’s cGMP manufacturing facility located in San Carlos, CA. Importantly, Xpress CF™ was nominated for best scientific innovation by World ADC in 2014 and Sutro Biopharma was named one of FierceBiotech’s Fierce 15 in 2014.
In addition to developing its own drug pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics. Last year, Sutro partnered with both Celgene and EMD Serono. This second partnership with Celgene is a multi-year collaboration focused on immuno-oncology and is valued at over $1 Billion. In the agreement, Celgene has an exclusive option to acquire Sutro. The deal with EMD Serono is a $300M+ collaboration to discover and develop novel antibody-drug conjugates for several targets in the field of oncology.
Key Management:
• William J. Newell, JD, CEO
• Trevor Hallam, PhD, Chief Scientific Officer
• Ed Albini, Chief Financial Officer
• Henry Heinsohn, VP Development & Manufacturing
• Aaron Sato, PhD, VP Research
• Nicki Vasquez, PhD, VP Alliance/Project Management
109 articles with Sutro Biopharma, Inc.
-
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
1/21/2021
Sutro Biopharma, Inc. today announced the dosing of the first patient in the dose-expansion cohort of Phase 1 study.
-
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
-
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
1/5/2021
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, Jan. 14, 2021 at 5:20 p.m. ET / 2:20 p.m. PT.
-
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
12/11/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the closing of its upsized public offering of 6,900,00
-
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
12/8/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the pricing of an underwritten public offering of 6,000,000
-
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
12/7/2020
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular lymphoma - Fred Hutchinson preclinical models with STRO-001 identifies CD74 as a potential target for the treatment of AML
-
Sutro Biopharma Announced Proposed Public Offering of 5 Million Shares of Common Stock
12/7/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a proposed underwritten public offering in which it int
-
As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, survival rates have also increased.
-
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12/3/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002
-
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
12/1/2020
- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro's Board -
-
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
11/24/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-gene
-
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
11/18/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced today the appointment of two executives to the Company's leadership team.
-
Sutro Biopharma to Participate in Four Upcoming Investor Conferences
11/11/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell , will participate in four upcoming virtual conferences in November and December of 2020. Presentations Details: 2020 Stifel Virtual Health
-
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
11/5/2020
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported its financial results for the quarter ended September 30, 2020 and its recent business highlights and developments.
-
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
9/21/2020
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held during the World ADC Digital Event.
-
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
9/9/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced further STRO-002 updated interim Phase 1 safety and preliminary efficacy data in ovarian cancer,
-
Sutro Biopharma to Present at Two Upcoming Investor Conferences - Sep 03, 2020
9/3/2020
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the following investor conferences in September
-
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
9/2/2020
Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression
-
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
8/25/2020
Sutro Biopharma, Inc. announced that it has achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.
-
Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
8/11/2020
Mr. Carlos Lugo promoted to Vice President of Quality and CMC Regulatory Operations Mr. Devendra Luhar promoted to Vice President of Manufacturing & Plant Operations